Cumberland Pharmaceuticals, a company that develops medicines for rare diseases, has announced that it is starting a national sales campaign for Talicia in the U.S. The company is now in charge of selling and promoting Talicia® in the country, under an agreement with RedHill Biopharma.
Talicia® is a prescription medicine used to treat a bacterial infection called Helicobacter pylori in adults, which can lead to stomach cancer. It is the only treatment that combines three medicines: omeprazole, amoxicillin, and rifabutin. Talicia® is now recommended as a first-choice treatment for this infection by the American College of Gastroenterology. The medicine is protected by a patent until 2042 and has a special market protection for 8 years.
The launch of Talicia® is part of Cumberland's plan to grow its business by promoting unique, FDA-approved medicines. The company will use its current sales team and marketing efforts to raise awareness among doctors, especially those who treat stomach-related issues.
Around 35% of adults in the U.S. are affected by the H. pylori infection, which causes about 11,000 deaths a year due to stomach cancer. Cumberland and its partner are working together to make sure more people can access this new treatment.
Executive Statement
According to A.J. Kazimi, CEO of Cumberland Pharmaceuticals, they believe this represents an important catalyst for the next phase of Talicia's growth. They are executing the full breadth of sales and marketing initiatives underway to support Talicia's continued momentum. Their focus is on strengthening prescription growth while expanding number of patients helped by this treatment.
